Stem Cells Therapy for Multiple Sclerosis.

Area of Science:

• Neuroscience
• Immunology
• Pathology

Background:

• Multiple sclerosis (MS) is a primary demyelinating disorder of the central nervous system (CNS).
• Pathological hallmarks include inflammatory plaques, white matter demyelination, and oligodendrocyte destruction.
• Axonal degeneration is a key process contributing to MS-related clinical deficits.

Purpose of the Study:

• To review the pathology of axonal degeneration in MS and its clinical manifestations.
• To discuss current pharmacological treatments for MS symptoms.
• To evaluate the efficacy of autologous hematopoietic stem cell transplantation (AHSCT) for aggressive MS and explore future challenges.

Main Methods:

• Literature review of MS pathology, focusing on axonal degeneration.
• Analysis of clinical symptoms linked to pathological changes.
• Review of pharmacological interventions for symptom management.
• Assessment of AHSCT outcomes in treatment-refractory MS patients.

Main Results:

• Axonal degeneration significantly contributes to the clinical progression and severity of MS.
• Pharmacological treatments aim to manage symptoms but may not halt disease progression.
• AHSCT demonstrates significant efficacy in aggressive MS patients who have not responded to conventional drug therapies.

Conclusions:

• Understanding axonal degeneration is crucial for managing MS.
• Symptomatic treatments are important, but novel therapeutic strategies are needed.
• AHSCT presents a viable and effective option for aggressive MS, warranting further research into its long-term challenges and optimization.